» Articles » PMID: 16947775

Endothelin Axis Polymorphisms in Patients with Scleroderma

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 2006 Sep 2
PMID 16947775
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the distribution of polymorphisms in the endothelin 1 (EDN1), endothelin receptor A (EDNRA) and endothelin receptor B (EDNRB) genes in systemic sclerosis (SSc; scleroderma) and SSc subsets.

Methods: Two hundred five patients with SSc and 255 healthy controls were screened for polymorphisms in EDN1, EDNRA, and EDNRB, using sequence-specific primer-polymerase chain reaction. The polymorphisms studied were at the following positions: for EDN1, -1370 (T-1370G) of the promoter, +138 of exon 1 (+138 A/-), +85 of exon 3 (E106E), and +23 of exon 5 (K198N); for EDNRA, -231 of exon 1 (G-231A), and +69(H323H) and +105 (E335E) of exon 6; for EDNRB, +2841 of exon 2 (EDNRB-3), -2547 of exon 3 (EDNRB-2), and -2446 of exon 3 (EDNRB-1).

Results: No significant differences between the SSc group as a whole and control subjects were observed for any of the investigated polymorphisms in EDN1, EDNRA, and EDNRB. However, compared with patients with limited cutaneous SSc, patients with diffuse skin involvement had an increased frequency of allele carriage of EDNRB-1A (76.8% versus 54.4%; P = 0.002), EDNRB-2A (79.7% versus 60.2%; P = 0.006), and EDNRB-3G (79.7% versus 56.6%; P = 0.001). Significantly increased carriage frequencies for EDNRA alleles H323H/C and E335E/A were observed in SSc patients with anti-RNA polymerase (anti-RNAP) antibodies, compared with both anti-RNAP-negative SSc patients (P < 0.05) and control subjects (P < 0.005).

Conclusion: The finding of associations between endothelin receptors A and B and distinct clinical and immunologic SSc subsets supports the role of endothelin and its receptors in the pathogenesis of SSc. However, these findings and their functional significance need to be confirmed and investigated in future studies.

Citing Articles

Clinical, Histologic, and Transcriptomic Evaluation of Sequential Fat Grafting for Morphea: A Nonrandomized Controlled Trial.

Liu J, Wang J, Zhang Q, Lu F, Cai J JAMA Dermatol. 2024; 160(4):425-433.

PMID: 38324287 PMC: 11024779. DOI: 10.1001/jamadermatol.2023.5908.


Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.

Muruganandam M, Ariza-Hutchinson A, Patel R, Sibbitt Jr W J Inflamm Res. 2023; 16:4633-4660.

PMID: 37868834 PMC: 10590076. DOI: 10.2147/JIR.S379815.


Specific Autoantibodies and Microvascular Damage Progression Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: Are There Peculiar Associations? An Update.

Hysa E, Campitiello R, Sammori S, Gotelli E, Cere A, Pesce G Antibodies (Basel). 2023; 12(1).

PMID: 36648887 PMC: 9844325. DOI: 10.3390/antib12010003.


Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis.

Cole A, Ong V, Denton C Clin Rev Allergy Immunol. 2022; 64(3):378-391.

PMID: 35648373 PMC: 10167155. DOI: 10.1007/s12016-022-08945-x.


Network based systems biology approach to identify diseasome and comorbidity associations of Systemic Sclerosis with cancers.

Islam M, Rahman M, Islam M, Islam M, Mamun M, Azad A Heliyon. 2022; 8(2):e08892.

PMID: 35198765 PMC: 8841363. DOI: 10.1016/j.heliyon.2022.e08892.